How to Get Liraglutide in Missouri: Prescriptions, Telehealth, and Pharmacies

What Is Liraglutide and Why Missouri Patients Are Seeking It

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist given as a once-daily subcutaneous injection. It lowers blood glucose in type 2 diabetes and, at the higher 3 mg dose marketed as Saxenda, produces clinically meaningful weight loss in adults with a body mass index (BMI) of 30 or higher, or BMI ≥27 with at least one weight-related comorbidity [1].

The SCALE Obesity and Prediabetes trial (N=3,731) published in the New England Journal of Medicine in 2015 showed that liraglutide 3 mg produced a mean weight loss of 8.4% at 56 weeks versus 2.8% with placebo (P<0.001). Roughly 63.2% of liraglutide-treated patients lost at least 5% of body weight, compared with 27.1% on placebo [2]. Those numbers shifted national prescribing dramatically, and Missouri clinicians now field liraglutide requests daily.

Interest has grown further since branded GLP-1 supplies tightened. Compounded liraglutide from 503A pharmacies has filled a meaningful gap, and Missouri law permits that pathway. The FDA acknowledges that compounded drugs from 503A pharmacies are not FDA-approved but may be dispensed legally on a patient-specific basis [3].

Who Can Prescribe Liraglutide in Missouri

Any Missouri-licensed prescriber with Schedule authority can write for liraglutide, which is not a controlled substance, meaning the legal bar is lower than for many weight-management drugs. Physicians (MD/DO), advanced practice registered nurses (APRNs), and physician assistants (PAs) all qualify [4].

Missouri passed SB 681 in 2024, granting full practice authority to APRNs who have completed at least 2 to 400 hours of supervised practice. Before that change, Missouri APRNs required a collaborative practice agreement with a physician to prescribe. Post-2024, a qualifying APRN can prescribe liraglutide independently, which is one reason telehealth platforms have expanded their Missouri nurse-practitioner rosters [5].

PAs in Missouri continue to operate under a collaborative agreement with a supervising physician per Missouri Revised Statutes Section 334.735, but that agreement does not prevent them from prescribing liraglutide after a legitimate patient-prescriber relationship is established [6].

The American Association of Clinical Endocrinology (AACE) 2023 Obesity guidelines state: "GLP-1 receptor agonists are recommended as first- or second-line pharmacotherapy for adults with obesity or overweight with complications, given their weight-loss efficacy and cardiometabolic benefits" [7]. That guideline is relevant because Missouri Medicaid auditors and commercial insurance reviewers cite AACE criteria when evaluating medical necessity.

Telehealth Prescribing for Liraglutide in Missouri

Missouri allows telehealth prescribing of liraglutide for both new and established patients, provided the prescriber conducts a real-time, two-way audio-visual evaluation that satisfies the standard of care. Audio-only visits do not meet the threshold for initiating a new controlled-substance prescription, but liraglutide is not scheduled, so some platforms complete intake via asynchronous questionnaire plus synchronous video confirmation [8].

Federal telehealth flexibilities introduced during the COVID-19 public health emergency have been extended through at least the end of 2025 under the Consolidated Appropriations Act, and Missouri-specific rules did not retract those expansions [9]. A Missouri prescriber may use a platform such as HealthRX to see a patient, confirm medical history, review labs, and generate an electronic prescription to a Missouri or out-of-state pharmacy licensed to ship into Missouri in a single visit.

Platforms typically charge a monthly membership or per-visit fee. Expect $75 to $200 for the initial evaluation. That fee is separate from the drug cost, which varies considerably between branded Saxenda (approximately $1,400 per month list price) and compounded liraglutide (often $150 to $400 per month depending on dose and pharmacy) [10].

Labs and Clinical Documentation Required Before Starting

Most Missouri prescribers order a standard metabolic panel before writing a first liraglutide prescription. The exact list varies by provider, but the following tests cover the key safety and efficacy baseline markers:

Required by the majority of prescribers:

• HbA1c (to distinguish prediabetes from overt type 2 diabetes and to guide dose titration)
• Fasting plasma glucose
• Comprehensive metabolic panel (CMP), including kidney and liver function
• Lipid panel (LDL, HDL, triglycerides)
• TSH (liraglutide carries an FDA boxed warning regarding thyroid C-cell tumors, and a baseline TSH identifies pre-existing thyroid disease) [11]
• BMI and waist circumference, documented in the chart

Ordered selectively:

• Serum amylase/lipase if the patient has a history of pancreatitis, which is a contraindication to liraglutide use [12]
• Urine pregnancy test for women of childbearing age (liraglutide is pregnancy category X equivalent under the 2008 FDA labeling framework; it should be stopped at least two months before a planned pregnancy) [11]
• Fasting insulin and C-peptide if type 1 diabetes needs to be ruled out

The FDA prescribing information for Saxenda specifies that liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [11]. Missouri prescribers must document that contraindication screen in every new chart.

A 2021 Endocrine Society clinical practice guideline on obesity pharmacotherapy recommends confirming that behavioral interventions have been attempted before initiating any GLP-1 agent, or that concurrent enrollment in a lifestyle program accompanies pharmacotherapy [13]. Many Missouri insurers require that documentation for prior authorization.

How Prior Authorization Works in Missouri for Liraglutide

Prior authorization (PA) is nearly universal for brand-name Saxenda in Missouri commercial plans and for Victoza when used off-label for weight loss. The PA process adds 5 to 14 business days to the timeline in most cases, though some plans offer expedited review within 72 hours for documented urgent clinical need.

A standard Missouri commercial PA submission for Saxenda (weight-management indication) typically requires:

1. Diagnosis code E66.9 (obesity, unspecified) or E66.01 (morbid obesity), with BMI documented in the chart within the last 90 days.
2. Evidence of at least 6 months of structured lifestyle intervention (diet records, referral to a registered dietitian, or enrollment in a commercial weight-loss program).
3. Documentation that other first-line agents were tried or are contraindicated. Some plans require a trial of orlistat or phentermine/topiramate first.
4. Prescriber attestation that the patient does not have a personal or family history of medullary thyroid carcinoma.
5. Lab results (HbA1c, CMP, lipid panel) dated within 12 months.

Missouri Medicaid (MO HealthNet) covers liraglutide (Victoza) for type 2 diabetes management but does not cover Saxenda for chronic weight management as of the date this article was last reviewed [14]. Patients seeking liraglutide for weight loss on MO HealthNet must either self-pay or pursue compounded liraglutide through a 503A pharmacy.

The American Diabetes Association's 2024 Standards of Care note: "For patients with type 2 diabetes who need greater glucose lowering than can be achieved with oral agents, GLP-1 receptor agonists should be considered before insulin in most cases" [15]. That statement is directly quoted in many MO HealthNet prior-authorization approval letters for the diabetes indication.

503A Compounding Pharmacies in Missouri

Missouri-licensed 503A compounding pharmacies can prepare liraglutide as a patient-specific compound when a valid prescription exists. These pharmacies operate under Missouri Board of Pharmacy oversight and must comply with USP 797 sterile-compounding standards for injectable preparations [16].

Key facts about 503A-compounded liraglutide in Missouri:

• The pharmacy must hold a current Missouri compounding pharmacy permit.
• Each prescription must be patient-specific (no pre-made batches for general sale).
• The compound is not FDA-approved, but the pharmacy's process must meet state and federal sterile-compounding standards.
• Compounded liraglutide is typically supplied as a multi-dose vial with a separate syringe, rather than the prefilled Novo Nordisk pen. Patients require brief injection training.
• Pricing ranges from approximately $150 to $400 per month for a 3 mg/day maintenance dose, compared with list-price Saxenda at roughly $1,400 per month [10].

The FDA has issued guidance clarifying that 503A pharmacies may not compound drugs that are essentially copies of commercially available drugs without a valid clinical difference, and that liraglutide's commercial availability should be assessed by the prescriber when writing the compound order [3]. Missouri prescribers typically note documented cost barrier or documented shortage access in the chart when directing patients to 503A compounders.

Out-of-state 503A pharmacies licensed to ship into Missouri may also fill Missouri prescriptions, provided they hold non-resident pharmacy permits from the Missouri Board of Pharmacy [16]. Several national telehealth-affiliated pharmacies operating on this model serve Missouri patients with two-to-five-day shipping timelines.

Step-by-Step: How to Get a Liraglutide Prescription in Missouri

Step 1. Choose your prescriber pathway. In-person endocrinologist, primary care physician, or obesity medicine specialist visits typically have the longest lead times (two to eight weeks for new patients in St. Louis or Kansas City). Telehealth platforms can schedule same-day or next-day appointments [8].

Step 2. Complete your pre-visit labs. Order labs at a local draw site (Quest, LabCorp, or hospital outpatient lab) before your appointment, or ask the platform to send a standing order. Results usually return within 24 to 48 hours from most Missouri draw sites.

Step 3. Attend the clinical visit. Expect 20 to 40 minutes for an initial obesity or metabolic health evaluation. The prescriber will review your BMI, weight history, labs, comorbidities, and contraindication screen, then discuss dose titration (liraglutide for weight loss starts at 0.6 mg/day for week 1, escalating by 0.6 mg each week to the 3 mg maintenance dose) [11].

Step 4. Submit prior authorization if using insurance. Your prescriber's office (or telehealth platform) handles PA submission. Gather your six-month lifestyle-intervention records before the visit to avoid delays.

Step 5. Fill your prescription. Branded Saxenda ships from specialty pharmacies or can be filled at CVS, Walgreens, or Walmart Pharmacy with a valid prescription. Compounded liraglutide ships from the prescribing platform's affiliated 503A pharmacy. Average shipping timeline to Missouri ZIP codes: two to four business days standard, one business day with overnight option.

Step 6. Begin dose titration. Week 1: 0.6 mg/day. Week 2: 1.2 mg/day. Weeks 3 through 5: continue escalating by 0.6 mg weekly to reach 3 mg/day by week 5. Nausea is the most common side effect during titration; a 2022 meta-analysis in Obesity Reviews (N=6,411 pooled participants across nine trials) found that slow titration reduced discontinuation due to gastrointestinal side effects by approximately 34% compared with faster escalation [17].

Transferring a Liraglutide Prescription to Missouri

Missouri allows prescription transfers from out-of-state pharmacies in most circumstances. For a non-controlled drug like liraglutide, a receiving Missouri pharmacy can accept a transferred prescription directly from another state's pharmacy. The receiving pharmacist contacts the originating pharmacy, documents the transfer, and fills the remaining refills. Electronic prescribing makes this straightforward: ask your telehealth prescriber to route future refills directly to a Missouri-based or Missouri-licensed pharmacy.

If you are moving to Missouri from another state where you had a standing liraglutide prescription, bring:

• Printed or electronic prescription records
• Lab work dated within the last 12 months
• Your most recent prescriber's contact information for pharmacy-to-pharmacy verification

Missouri Board of Pharmacy rules do not require a new in-state patient-prescriber visit to transfer a non-scheduled prescription, but many telehealth platforms require an annual check-in visit to continue prescribing [16].

Pricing and Cost-Reduction Strategies in Missouri

Branded Saxenda carries a list price near $1,400 per month. Without insurance, most Missouri patients find that cost prohibitive. The following strategies reduce out-of-pocket exposure:

Novo Nordisk Patient Assistance. The Saxenda savings card reduces co-pay to as low as $25 per 30-day supply for commercially insured patients who meet income criteria. Uninsured patients may qualify for the Novo Nordisk Patient Assistance Program (PAP) at no cost [18].

Goodrx and discount cards. GoodRx coupons bring 30-day Victoza (1.8 mg) to roughly $400 to $600 at Missouri pharmacies as of mid-2025. Saxenda 3 mg discount pricing varies more widely by pharmacy location within Missouri.

Compounded liraglutide. As noted above, 503A compounded vials typically run $150 to $400 per month. The tradeoff is the absence of FDA approval for the compound and the requirement for syringe-and-vial administration rather than a prefilled pen.

Missouri Medicaid. Victoza for type 2 diabetes is covered under MO HealthNet for patients who meet clinical criteria. Weight-management use (Saxenda) is not covered [14].

A 2022 JAMA Internal Medicine study found that cost remained the primary driver of GLP-1 discontinuation in the United States, with 43% of patients who stopped citing affordability as the principal reason [19]. Addressing cost before the first prescription is written saves the prescriber time and gives the patient realistic expectations.

Monitoring After Starting Liraglutide in Missouri

Starting liraglutide is not the end of the clinical interaction. Missouri prescribers following AACE 2023 obesity guidelines typically schedule:

• A four-week check-in to assess tolerability, weight response, and injection technique.
• HbA1c and fasting glucose at 12 weeks for patients using liraglutide for diabetes.
• Weight and BMI at every visit; the Endocrine Society defines an inadequate response as less than 5% weight loss at 16 weeks on the maintenance dose, which should prompt a reassessment of the treatment plan [13].
• Heart rate monitoring: liraglutide raises resting heart rate by an average of two to three beats per minute in some patients. The LEADER trial (N=9,340, median follow-up 3.8 years) found that liraglutide reduced major adverse cardiovascular events (MACE) by 13% versus placebo (hazard ratio 0.87 to 95% CI 0.78-0.97, P<0.001 for non-inferiority and P=0.01 for superiority) in adults with type 2 diabetes and high cardiovascular risk [20]. That cardiovascular benefit is part of why Missouri cardiologists and endocrinologists often co-prescribe liraglutide in high-risk patients.
• Annual TSH to monitor thyroid function, especially in patients with pre-existing subclinical hypothyroidism [11].

Missouri telehealth platforms with in-state prescribers can handle all follow-up visits remotely, provided the prescriber has access to updated lab data and the patient has a local draw site for periodic blood work.

Liraglutide vs. Semaglutide in Missouri: Practical Differences

Semaglutide (Ozempic for diabetes, Wegovy for weight management) has largely captured public attention, but liraglutide remains the right choice for specific Missouri patients:

• Patients who tolerate once-daily dosing better than once-weekly injections (some individuals experience more pronounced GI side effects on the weekly semaglutide peak).
• Patients who are on Victoza for glycemic control and do not need the higher weight-loss magnitude.
• Patients for whom semaglutide supply is constrained in their Missouri ZIP code.
• Patients using a 503A pharmacy where compounded liraglutide is available and compounded semaglutide has been restricted by FDA guidance [3].

The SCALE trial showed 8.4% mean weight loss with liraglutide 3 mg at 56 weeks [2]. The STEP-1 trial (N=1,961) showed 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [21]. The absolute difference is real. Missouri patients with BMI ≥40 or significant metabolic syndrome may produce better outcomes on semaglutide, while liraglutide remains appropriate for those with modest weight-loss targets or specific tolerability profiles.